2
项与 纳武利尤单抗生物类似药(Biocad) 相关的临床试验A Double-Blind, Randomized Clinical Study of the Efficacy and Safety of BCD-263 and Opdivo® As Monotherapy in Subjects with Advanced Melanoma of the Skin
The aim of the study BCD-263-2/UNIVERSE is to demonstrate comparable efficacy and similar safety and immunogenicity profile of BCD-263 and Opdivo after repeated intravenous doses in subjects with advanced unresectable or metastatic melanoma of the skin.
A Double-Blind, Randomized Clinical Study of the Pharmacokinetics and Safety of BCD-263 and Opdivo® as Monotherapy in Subjects With Advanced Melanoma of the Skin
The aim of the study BCD-263-1 is to prove the comparability of the pharmacokinetics and similarity of the safety, immunogenicity and pharmacodynamic profiles of BCD-263 and Opdivo following intravenous administration to subjects with advanced unresectable or metastatic melanoma of the skin. The study will have randomized, double-blind design with parallel assignment.
100 项与 纳武利尤单抗生物类似药(Biocad) 相关的临床结果
100 项与 纳武利尤单抗生物类似药(Biocad) 相关的转化医学
100 项与 纳武利尤单抗生物类似药(Biocad) 相关的专利(医药)
100 项与 纳武利尤单抗生物类似药(Biocad) 相关的药物交易